In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AlloVir (ALVR – Research Report), with a price target of $27.00. The company’s shares closed yesterday at $1.75.
Raymond covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Ardelyx, and Amgen. According to TipRanks, Raymond has an average return of 1.6% and a 47.76% success rate on recommended stocks.
AlloVir has an analyst consensus of Strong Buy, with a price target consensus of $21.33.
See Insiders’ Hot Stocks on TipRanks >>
ALVR market cap is currently $172.3M and has a P/E ratio of -1.02.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALVR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AlloVir (ALVR) Company Description:
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm’s pipeline includes ALVR106, ALVR109, ALVR108, and others. The company’s product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Read More on ALVR:
